The pipeline of new drug candidates has never been fuller. Innovative HTS discovery strategies and emerging technologies such as genomics, combinatorial chemistry and bioinformatics are having a tremendous impact. But all this front-end productivity is also having downstream repercussions. Laboratory workload is increasing exponentially more drugs for testing, earlier testing, parallel paths, and broader filing strategies.
Compliance requirements add to the burden, and are becoming increasingly more rigorous.
As lab managers are told to work smarter and to do more with less, there is no relief in sight. The industry is challenged to implement new strategies and technologies and completely enter the electronic age. Something is missing. It s not just that there s more work to be done. Increasing regulatory demands are forcing companies to divert valuable resources from their primary mission to compliance-related activities.